-+ 0.00%
-+ 0.00%
-+ 0.00%

Daiichi Sankyo’s Enhertu wins EU approval for tumor-agnostic HER2+ metastatic solid tumors

PUBT·06/29/2026 06:30:26
Listen to the news
Daiichi Sankyo’s Enhertu wins EU approval for tumor-agnostic HER2+ metastatic solid tumors
  • EU cleared Enhertu as a tumor-agnostic HER2-directed antibody-drug conjugate for previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumors.
  • Label covers adults with no satisfactory treatment options; decision draws on phase 2 data showing response rates of about 47% to 53%.
  • AstraZeneca owes Daiichi Sankyo a USD 25 million milestone tied to the new EU indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606290230BIZWIRE_USPR_____20260626_BW073312) on June 29, 2026, and is solely responsible for the information contained therein.